Uber, the ride-hailing startup, is reportedly gearing up to make a US$3 billion bid for Careem Networks, the Dubai-based ride-hailing company.
According to a report in Reuters, citing sources familiar with the deal, Uber could make the offer during the early part of the week. Uber is offering US$1.4 billion in cash and US$1.7 billion in convertible notes, which can be converted to Uber shares at a price of US$55 per share. Neither side commented on the report.
Uber’s revenue was US$11.3 billion in 2018, while its gross bookings from rides totaled US$50 billion. However, the company lost US$3.3 billion, excluding gains from the sale of its business units in Russia and Southeast Asia.
The potential move comes as Uber is gearing up to launch an initial public offering (IPO) that could value the ride-hailing startup as high as US$120 billion, and as rival Lyft is also gearing up for its own IPO. According to recent reports, Lyft is set to launch its roadshow ahead of an IPO, and could get a valuation of between US$21 billion and US$23 billion. Lyft aims to trade on the Nasdaq Stock Market with the symbol LYFT by the end of March.
Citing sources, Reuters reported at the time that Lyft will present itself to investors as a better bet than its chief ride-hailing rival Uber, which has branched out into areas such as food delivery and freight hauling. As part of the IPO, Lyft will offer one-time cash bonuses to drivers, who can use them to buy shares if desired. The company is set to pay the bonuses to employees around March 19, with those who have logged at least 10,000 rides by February 25 eligible for a US$1,000 bonus and those with 20,000 rides to receive a US$10,000 bonus.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas